Related Experiment Video
Updated: Jun 2, 2026

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
Published on: August 12, 2025
Pentraxins: CRP and PTX3 and cardiovascular disease
Yuichiro Maekawa1, Toshiyuki Nagai, Atsushi Anzai
1Department of Cardiology, Keio University School of Medicine, Shinanomahi 35, Shinjuku-ku, Tokyo 160-8582, Japan. ymaekawa@gmail.com
Insights
C-reactive protein (CRP) and pentraxin3 (PTX3) are key biomarkers for cardiovascular disease (CVD) diagnosis and prognosis. Monitoring these inflammatory markers aids in understanding CVD progression and treatment effectiveness.
Area of Science:
- Biochemistry
- Immunology
- Cardiology
Background:
- Pentraxins, including C-reactive protein (CRP), serum amyloid P (SAP), and pentraxin3 (PTX3), are implicated in cardiovascular disease (CVD) pathogenesis.
- Inflammation and innate immunity play crucial roles in the development of CVD.
Purpose of the Study:
- To review the clinical implications and roles of CRP and PTX3 in cardiovascular disease.
- To highlight their utility as biomarkers for diagnosis and prognosis in CVD.
Main Methods:
- Literature review of major findings on CRP and PTX3 in CVD.
- Discussion of experimental and clinical data regarding pentraxin roles in CVD pathophysiology.
Main Results:
- Elevated circulating levels of CRP and PTX3 offer prognostic information across various clinical scenarios.
- These biomarkers facilitate the diagnosis of CVD, particularly ischemic heart disease and heart failure.
- Changes in pentraxin levels over time can indicate treatment response and therapeutic mechanisms.
Conclusions:
- CRP and PTX3 are valuable biomarkers for CVD management.
- Understanding pentraxin involvement in inflammation and immunity provides insights into CVD mechanisms.
- Monitoring CRP and PTX3 levels is essential for assessing CVD prognosis and treatment efficacy.
Abstract:
The pentraxins, C-reactive protein (CRP), serum amyloid P (SAP) and pentraxin3 (PTX3) are useful biomarkers for cardiovascular disease (CVD), particularly ischemic heart disease and heart failure, and are deeply involved in the pathogenesis of CVD linked to inflammation and innate immunity. Circulating elevated pentraxins, especially CRP and PTX3 levels can provide prognostic information for a variety of clinical settings and facilitate the diagnosis of CVD. Changes in these levels over time are also important indicators of pharmacological therapy, and may indicate the mechanisms by which pentraxins directly or indirectly affect the pathophysiology of CVD in an experimental setting. Here, we discuss major relevant findings associated with the clinical implications of CRP and PTX3 and their role in CVD.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Clinical Significance of Antibiotic Resistance
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Global Regulatory Systems
Acute Inflammation III: Local and Systemic Effects
